<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Ellsworth CR</submitter><funding>American Heart Association</funding><funding>American Heart Association-American Stroke Association</funding><funding>NHLBI NIH HHS</funding><funding>NIH</funding><funding>U.S. Department of Veterans Affairs</funding><funding>NIH HHS</funding><pagination>405</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11405604</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>81(1)</volume><pubmed_abstract>Emerging evidence indicates that activation of complement system leading to the formation of the membrane attack complex (MAC) plays a detrimental role in COVID-19. However, their pathogenic roles have never been experimentally investigated before. We used three knock out mice strains (1. C3&lt;sup>-/-&lt;/sup>; 2. C7&lt;sup>-/-&lt;/sup>; and 3. Cd59ab&lt;sup>-/-&lt;/sup>) to evaluate the role of complement in severe COVID-19 pathogenesis. C3 deficient mice lack a key common component of all three complement activation pathways and are unable to generate C3 and C5 convertases. C7 deficient mice lack a complement protein needed for MAC formation. Cd59ab deficient mice lack an important inhibitor of MAC formation. We also used anti-C5 antibody to block and evaluate the therapeutic potential of inhibiting MAC </pubmed_abstract><journal>Cellular and molecular life sciences : CMLS</journal><pubmed_title>Enhanced complement activation and MAC formation accelerates severe COVID-19.</pubmed_title><pmcid>PMC11405604</pmcid><funding_grant_id>R01 HL165265</funding_grant_id><funding_grant_id>P51 OD011104</funding_grant_id><funding_grant_id>R01HL165265</funding_grant_id><funding_grant_id>HL139930</funding_grant_id><funding_grant_id>AHA962950</funding_grant_id><funding_grant_id>R01DK129881</funding_grant_id><funding_grant_id>IK6BX005235</funding_grant_id><funding_grant_id>962950</funding_grant_id><funding_grant_id>P51OD011104-62</funding_grant_id><pubmed_authors>Qian C</pubmed_authors><pubmed_authors>Khatun MS</pubmed_authors><pubmed_authors>Wang C</pubmed_authors><pubmed_authors>Maness NJ</pubmed_authors><pubmed_authors>Islamuddin M</pubmed_authors><pubmed_authors>Halperin JA</pubmed_authors><pubmed_authors>Qin X</pubmed_authors><pubmed_authors>Liu S</pubmed_authors><pubmed_authors>Kolls JK</pubmed_authors><pubmed_authors>Xiao MT</pubmed_authors><pubmed_authors>Blair RV</pubmed_authors><pubmed_authors>Chen Z</pubmed_authors><pubmed_authors>Tomlinson S</pubmed_authors><pubmed_authors>Ellsworth CR</pubmed_authors></additional><is_claimable>false</is_claimable><name>Enhanced complement activation and MAC formation accelerates severe COVID-19.</name><description>Emerging evidence indicates that activation of complement system leading to the formation of the membrane attack complex (MAC) plays a detrimental role in COVID-19. However, their pathogenic roles have never been experimentally investigated before. We used three knock out mice strains (1. C3&lt;sup>-/-&lt;/sup>; 2. C7&lt;sup>-/-&lt;/sup>; and 3. Cd59ab&lt;sup>-/-&lt;/sup>) to evaluate the role of complement in severe COVID-19 pathogenesis. C3 deficient mice lack a key common component of all three complement activation pathways and are unable to generate C3 and C5 convertases. C7 deficient mice lack a complement protein needed for MAC formation. Cd59ab deficient mice lack an important inhibitor of MAC formation. We also used anti-C5 antibody to block and evaluate the therapeutic potential of inhibiting MAC </description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 Sep</publication><modification>2026-06-02T23:16:51.024Z</modification><creation>2025-04-04T12:09:25.372Z</creation></dates><accession>S-EPMC11405604</accession><cross_references><pubmed>39284944</pubmed><doi>10.1007/s00018-024-05430-w</doi></cross_references></HashMap>